Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas

Metastatic pheochromocytomas and paragangliomas (MPPGs) are rare endocrine malignancies that are associated with high rates of morbidity and mortality because of their large tumor burden and location, progression, and release of catecholamines. Systemic therapies for MPPGs are limited. MPPGs are cha...

Full description

Bibliographic Details
Main Authors: Camilo Jimenez, Vivek Subbiah, Bettzy Stephen, Junsheng Ma, Denai Milton, Mingxuan Xu, Abdualrazzak Zarifa, Fechukwu Omolara Akhmedzhanov, Apostolia Tsimberidou, Mouhammed Amir Habra, Jordi Rodon Anhert, Siqing Fu, Aung Naing
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cancers
Subjects:
PD-1 inhibition
pembrolizumab
metastatic pheochromocytoma
metastatic paraganglioma
pseudohypoxia
Online Access:https://www.mdpi.com/2072-6694/12/8/2307

Internet

https://www.mdpi.com/2072-6694/12/8/2307

Similar Items